| $350M | ||
| $217M | ||
| $172M | ||
| $107M | ||
| $104M | ||
| $100M |
Buys | $109,119,870 | 20 | 47 |
Sells | $2,859,573 | 23 | 53 |
| RA CAPITAL MANAGEMENT, L.P. | 19 | $92.62M | 0 | $0 | $92.62M | |
| GC Corp. | 10 percent owner | 1 | $16.5M | 0 | $0 | $16.5M |
| Raymon Heather | SVP, Research and Development | 0 | $0 | 1 | $27,879 | $-27,879 |
| Banerjee Subhashis | Chief Medical Officer | 0 | $0 | 6 | $191,696 | $-191,696 |
| Bush Jennifer | COO, CLO, Compliance Officer | 0 | $0 | 4 | $265,296 | $-265,296 |
| Horan Christopher | Chief Tech Operations Officer | 0 | $0 | 4 | $292,987 | $-292,987 |
| Aslan Fred | President and CEO | 0 | $0 | 8 | $2.08M | $-2.08M |
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific …
Over the last 12 months, insiders at Artiva Biotherapeutics, Inc. have bought $109.12M and sold $2.86M worth of Artiva Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Artiva Biotherapeutics, Inc. have bought $137.06M and sold $1.54M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $92.62M. GC Corp. (10 percent owner) — $16.5M.
The last purchase of 24,944 shares for transaction amount of $247,694 was made by RA CAPITAL MANAGEMENT, L.P. () on 2026‑07‑31.
| 2026-11-02 | Sale | Aslan Fred | Chief Executive Officer | 62,178 0.1574% | $4.18 | $259,972 | +0.45% | |
| 2026-11-02 | Sale | Bush Jennifer | COO, CLO, Compliance Officer | 8,439 0.0214% | $4.18 | $35,284 | +0.45% | |
| 2026-11-02 | Sale | Horan Christopher | Chief Tech Operations Officer | 10,423 0.0264% | $4.18 | $43,580 | +0.45% | |
| 2026-11-02 | Sale | Banerjee Subhashis | Chief Medical Officer | 1,110 0.0028% | $4.18 | $4,641 | +0.45% | |
| 2026-10-06 | Sale | Aslan Fred | Chief Executive Officer | 23,463 0.0475% | $7.20 | $168,880 | -16.02% | |
| 2026-10-05 | Sale | Aslan Fred | Chief Executive Officer | 61,696 0.1501% | $6.84 | $421,828 | -13.74% | |
| 2026-10-05 | Sale | Bush Jennifer | COO, CLO, Compliance Officer | 8,370 0.0204% | $6.84 | $57,227 | -13.74% | |
| 2026-10-05 | Sale | Horan Christopher | Chief Tech Operations Officer | 10,340 0.0252% | $6.84 | $70,697 | -13.74% | |
| 2026-10-05 | Sale | Banerjee Subhashis | Chief Medical Officer | 1,099 0.0027% | $6.84 | $7,514 | -13.74% | |
| 2026-09-08 | Sale | Aslan Fred | Chief Executive Officer | 23,429 0.0596% | $10.92 | $255,746 | -36.72% | |
| 2026-09-03 | Sale | Aslan Fred | Chief Executive Officer | 61,888 0.1269% | $11.16 | $690,392 | -37.42% | |
| 2026-09-03 | Sale | Bush Jennifer | COO, CLO, Compliance Officer | 8,391 0.0172% | $11.16 | $93,606 | -37.42% | |
| 2026-09-03 | Sale | Horan Christopher | Chief Tech Operations Officer | 10,366 0.0213% | $11.16 | $115,638 | -37.42% | |
| 2026-09-03 | Sale | Banerjee Subhashis | Chief Medical Officer | 1,100 0.0023% | $11.16 | $12,271 | -37.42% | |
| 2026-08-27 | Sale | Banerjee Subhashis | Chief Medical Officer | 8,222 0.021% | $12.01 | $98,736 | -41.12% | |
| 2026-08-18 | Sale | Banerjee Subhashis | Chief Medical Officer | 429 0.0009% | $12.00 | $5,148 | -38.36% | |
| 2026-07-31 | RA CAPITAL MANAGEMENT, L.P. | 24,944 0.0992% | $9.93 | $247,694 | -15.64% | |||
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P. | 20,824 0.084% | $9.99 | $208,032 | -14.12% | |||
| 2026-07-24 | RA CAPITAL MANAGEMENT, L.P. | 41,319 0.1665% | $9.99 | $412,777 | -11.17% | |||
| 2026-07-23 | RA CAPITAL MANAGEMENT, L.P. | 59,880 0.2408% | $9.96 | $596,405 | -6.56% |
| RA CAPITAL MANAGEMENT, L.P. | 17329570 35.446% | $72.78M | 20 | 0 | <0.0001% | |
| GC Corp. | 10 percent owner | 4391969 8.9833% | $18.45M | 2 | 0 | <0.0001% |
| Huh Yong-Jun | director | 3306900 6.7639% | $13.89M | 1 | 0 | <0.0001% |
| venBio Global Strategic Fund III, L.P. | 10 percent owner | 1936637 3.9612% | $8.13M | 1 | 0 | <0.0001% |
| 5AM Partners VI, LLC | 10 percent owner | 1182054 2.4178% | $4.96M | 1 | 0 | <0.0001% |
$22,710,871 | 107 | 8.53% | $220.62M | |
$168,352,523 | 35 | 13.58% | $218.79M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$74,231,875 | 30 | 40.62% | $183.78M | |
$54,828,550 | 26 | -13.88% | $201.12M |
| Increased Positions | 10 | +15.87% | 732,601 | +4.04% |
| Decreased Positions | 27 | -42.86% | 2M | -10.63% |
| New Positions | 6 | New | 468,430 | New |
| Sold Out Positions | 12 | Sold Out | 1M | Sold Out |
| Total Postitions | 46 | -26.98% | 17M | -6.59% |